Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4.

Elisa A. Rozeman,Marnix H. Geukes Foppen,SuFey Ong,Ruben Lacroix,Patrick Danaher,Annegien Broeks,Alessandra Cesano,S. Wilgenhof,Johannes V. Van Thienen,John B. A. G. Haanen,Sarah Warren,Christian U. Blank

Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4.

2018

Elisa A. Rozeman
Marnix H. Geukes Foppen
SuFey Ong
Ruben Lacroix
Patrick Danaher
Annegien Broeks
Alessandra Cesano
S. Wilgenhof
Johannes V. Van Thienen
John B. A. G. Haanen
Sarah Warren
Christian U. Blank

9585Background: The immune checkpoint inhibitors (CI) anti-CTLA-4 (ipilimumab [IPI]) and anti-PD-1 (pembrolizumab [PEM] and nivolumab [NIVO]) have improved survival in advanced melanoma patients (p...

Keywords:

Melanoma
Immune system
Gene
Cancer research
Pathology
CTLA-4
Medicine
improved survival
Pembrolizumab
advanced melanoma
immune gene
Ipilimumab
anti ctla 4
anti pd 1
Nivolumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations